These data show that proliferation and/or survival of basal breast cancer cells in vivo could be suppressed by the depletion of ARHGEF11 isoform, suggesting that A11exon38(+) could be a target for therapy of invasive breast cancer. The gene discussed is ARHGEF11; the disease is breast carcinoma.